Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Meredith O'Shea"'
Autor:
Mireia Diaz, Jane J. Kim, Hélène Sancho-Garnier, Muhieddine Seoud, Monisha Sharma, Meredith O'Shea, Steven Sweet
Publikováno v:
Vaccine. 31:G65-G77
To date, no studies have evaluated the cost-effectiveness of human papillomavirus (HPV) vaccination in countries in the Extended Middle East and North Africa (EMENA) region. We synthesized population and epidemiologic data for 20 EMENA countries usin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d80495c89d577789264ccbb11cf28b36
https://doi.org/10.1016/j.vaccine.2012.06.096
https://doi.org/10.1016/j.vaccine.2012.06.096
Autor:
Sue J. Goldie, Carol Levin, N. Rocio Mosqueira-Lovón, Jesse Ortendahl, Jane Kim, Meredith O'Shea, Mireia Diaz Sanchez, Maria Ana Mendoza Araujo
Publikováno v:
Revista Panamericana de Salud Pública, Vol 32, Iss 6, Pp 426-434 (2012)
OBJECTIVE: To estimate the benefits, cost-effectiveness (i.e., value for money), and required financial costs (e.g., affordability) of adding human papillomavirus (HPV) vaccination to Peru's cervical cancer screening program. METHODS: Evidence (e.g.,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doajarticles::d173444438819fe3cf980a21bfe7978a
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892012001400006
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892012001400006
Autor:
F. Xavier Bosch, Jane J. Kim, Sue J. Goldie, Meredith O'Shea, Jesse D. Ortendahl, Mireia Diaz, Silvia de Sanjosé
Publikováno v:
European Journal of Cancer. 46:2973-2985
Background In Spain, prophylactic vaccination against human papillomavirus (HPV) types 16 and 18 is being offered free-of-charge to one birth cohort of girls aged 11–14. Screening is opportunistic (annual/biannual) contributing to social and geogra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2056c27ce11b3f0d30ae328e15fdc726
https://doi.org/10.1016/j.ejca.2010.06.016
https://doi.org/10.1016/j.ejca.2010.06.016
Autor:
F. Xavier Bosch, Meredith O'Shea, Jeremy D. Goldhaber-Fiebert, Katie E. Kobus, Sue J. Goldie, Silvia de Sanjosé, Joshua A. Salomon, Jane J. Kim, Eduardo L. Franco
Publikováno v:
Vaccine. 25:6257-6270
We use an empirically calibrated model to estimate the cost-effectiveness of cervical cancer prevention in Brazil, a country with a high cervical cancer burden. Assuming 70% coverage, HPV 16, 18 vaccination of adolescent girls is expected to reduce t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad69aea2f77ba2c2cd68198337470455
https://doi.org/10.1016/j.vaccine.2007.05.058
https://doi.org/10.1016/j.vaccine.2007.05.058
Publikováno v:
Vaccine. 31
Using population and epidemiologic data for 48 countries in sub-Saharan Africa, we used a model-based approach to estimate cervical cancer cases and deaths averted, disability-adjusted life years (DALYs) averted and incremental cost-effectiveness rat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26b0918ee551c6d68baadec0647f923e
https://pubmed.ncbi.nlm.nih.gov/24331749
https://pubmed.ncbi.nlm.nih.gov/24331749
Autor:
Jane J. Kim, Philip E. Castle, Meredith O'Shea, Sue J. Goldie, Mireia Diaz, Jesse D. Ortendahl, Nicole G. Campos
Eastern Africa has the world's highest cervical cancer incidence and mortality rates. We used epidemiologic data from Kenya, Mozambique, Tanzania, Uganda, and Zimbabwe to develop models of HPV-related infection and disease. For each country, we asses
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7857b5a3220095461850a6fb29c63440
https://europepmc.org/articles/PMC3314721/
https://europepmc.org/articles/PMC3314721/
Autor:
Sue J, Goldie, Carol, Levin, N Rocio, Mosqueira-Lovón, Jesse, Ortendahl, Jane, Kim, Meredith, O'Shea, Mireia, Diaz Sanchez, Maria Ana, Mendoza Araujo
Publikováno v:
Revista panamericana de salud publica = Pan American journal of public health. 32(6)
To estimate the benefits, cost-effectiveness (i.e., value for money), and required financial costs (e.g., affordability) of adding human papillomavirus (HPV) vaccination to Peru's cervical cancer screening program.Evidence (e.g., coverage, delivery c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::885d6bdd5bfa56cb149efc611fec65fa
https://pubmed.ncbi.nlm.nih.gov/23370186
https://pubmed.ncbi.nlm.nih.gov/23370186
Publikováno v:
Reproductive health matters. 16(32)
Approximately 70% of cases of cervical cancer worldwide are caused by genotypes 16 and 18 of human papillomavirus (HPV), which is sexually transmitted. With the availability of an effective vaccine against these HPV types, there is real hope for redu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a89ed3e10fadcb2f4699a5b63251b4c0
https://pubmed.ncbi.nlm.nih.gov/19027626
https://pubmed.ncbi.nlm.nih.gov/19027626
Publikováno v:
Vaccine. 26(32)
The risk of dying from cervical cancer is disproportionately borne by women in developing countries. Two new vaccines are highly effective in preventing HPV 16,18 infection, responsible for approximately 70% of cervical cancer, in girls not previousl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::79036c1bcd18eae0e7a50bece2e3ca15
https://pubmed.ncbi.nlm.nih.gov/18550229
https://pubmed.ncbi.nlm.nih.gov/18550229
Publikováno v:
Vaccine. 26(32)
Using mathematical models of cervical cancer for the northern and southern regions of Vietnam, we assessed the cost-effectiveness of cervical cancer prevention strategies and the tradeoffs between a national and region-based policy in Vietnam. With 7
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b74cc73084211e28f0e1764142f4fcfe
https://pubmed.ncbi.nlm.nih.gov/18602731
https://pubmed.ncbi.nlm.nih.gov/18602731